Drug profile · INN
finafloxacin
XTORO
finafloxacin (XTORO) is a dna gyrase inhibitor. Route of administration: otic. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — finafloxacin
- US status
- approved
- Class
- —
- Route
- OTIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
finafloxacin (XTORO) is a dna gyrase inhibitor. Route of administration: otic. Current US regulatory status: approved.
Key facts
INN finafloxacin
Brand XTORO
Mechanism DNA gyrase inhibitor
Target DNA gyrase
Route OTIC
Formulation SUSPENSION/DROPS
Mechanism of action
DNA gyrase inhibitor
Primary target: DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is finafloxacin?
finafloxacin (XTORO) is a dna gyrase inhibitor. Route of administration: otic. Current US regulatory status: approved.
What is the brand name for finafloxacin?
XTORO is a marketed brand name for finafloxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of finafloxacin?
finafloxacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.